Abstract

Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma

Author(s): Teeranachaideekul Veerawat, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn

Issue: Jan/Feb 2021 - Volume 25, Number 1

Page(s): 62-72

Download in electronic PDF format for $75
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 1
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 2
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 3
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 4
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 5
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 6
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 7
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 8
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 9
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 10
  • Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 11

Abstract

Concentrated 7% w/w a-arbutin cream was formulated and evaluated using O/W and W/O emulsion bases as an extemporaneous preparation for melasma treatment. Cream bases were formulated with two pH values, 4.0 and 5.5, using a hot process. The stability of the creams was studied for 60 days under three storage conditions (i.e., 2°C to 8°C, 30°C, 40°C). Cream characteristics and all aspects of product stability including physical, chemical, and microbial were investigated. Stability was defined as no dramatic change in color, viscosity, pH, and no visible microbial growth. For stability, at least 90% of the initial a-arbutin concentration quantified by stability-indicating high-performance liquid chromatography must be obtained. It was found that pH had no influence on the a-arbutin or formulations’ stability. All formulations had a-arbutin remaining higher than 90% (approximately 92%) after being stored for 60 days in all storage conditions with no significant changes in pH or viscosity. All samples complied with the microbial limits test for nonsterile pharmaceutical preparation for cutaneous products. However, a color change was detected in O/W and W/O emulsions, especially at 40°C storage condition within 28 and 14 days, respectively. Drug crystals were observed in W/O emulsion stored at 2°C to 8°C. Concerning the in vitro drug release, a-arbutin was released from O/W emulsion but not from W/O emulsion. From the above results, the O/W emulsion that was developed in this study can be used as a cream base for concentrated a-arbutin as an extemporaneous preparation. The developed a-arbutin cream prepared using O/W emulsions can be used as an extemporaneous preparation with a beyond-use date of 60 days when stored at room temperature (30°C) and in the refrigerator (2°C to 8°C).

Related Keywords

  • α-arbutin
  • alpha arbutin cream
  • hydroquinone derivative
  • tyrosinase inhibitor
  • melanin
  • topical preparations
  • melasma
  • skin pigment disorders
  • hyperpigmentation
  • physical stability
  • chemical stability
  • microbial growth

Related Categories

  • LEGAL
  • PEER-REVIEWED
  • SUPPORT
  • QUALITY CONTROL

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2021
Pg. 62-72
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Author(s): Teeranachaideekul Veerawat, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
Jul/Aug 2003
Pg. 266-270
Sensitization Therapy for Warts
Author(s): Kuntz Rachael
Sep/Oct 2009
Pg. 386-389
Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Author(s): Williams LaVonn A, Fokken Dawn
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
Nov/Dec 2014
Pg. 512-515
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Author(s): Heustess Allie, Asbill Scott, Eagerton David, Arnold John
Jul/Aug 2014
Pg. 332-340
Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream
Author(s): Polonini Hudson C, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B
Jan/Feb 2022
Pg. 54
Deoxyarbutin 3% Anhydrous Emulsion
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
Nov/Dec 2003
Pg. 460-463
View Sample
Basics of Compounding for Dry-Skin Conditions
Author(s): Allen Loyd V Jr
Nov/Dec 2018
Pg. 446-454
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Author(s): Zur Eyal
Nov/Dec 2020
Pg. 446-448
NASEM Report on Compounded Topical Pain Creams
Author(s): Allen Loyd V Jr
Sep/Oct 2007
Pg. 425
Nondetergent Neutral Dry Skin Cream
Author(s): Allen Loyd V Jr
Jan/Feb 2000
Pg. 72-75
Physicochemical Stability of Compounded Creams Containing alpha-Hydroxy Acids
Author(s): de Villiers Melgardt M, Narsai Kirti, van der Watt Jakkie G
Sep/Oct 2015
Pg. 357-365
Novel Approaches to Topical Psoriasis Therapy
Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Jul/Aug 2020
Pg. 320
Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream)
Author(s): Allen Loyd V Jr
Jul/Aug 2002
Pg. 303-304
Topical Oil-in-Water Cream Bases, Featured Excipient:
Author(s): Allen Loyd V Jr
Jul/Aug 2002
Pg. 255-256
Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women
Author(s): Mason Dave
Nov/Dec 2007
Pg. 505
Breast Care Cream
Author(s): Allen Loyd V Jr
Jul/Aug 2021
Pg. 336-343
Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Author(s): Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
Sep/Oct 2016
Pg. 412
Progesterone 10% Cream
Author(s): Allen Loyd V Jr